CClinicalTrials.gg
CompletedNCT05202470Updated Jun 15, 2023

Effectiveness of Telehealth Program in Patients With Type 2 Diabetes

An interventional study of TE and CE in Type 2 Diabetes, sponsored by Muğla Sıtkı Koçman University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Muğla Sıtkı Koçman University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Diabetes education is of great importance in the effective management of diabetes. Studies have shown that patients given diabetes education have positive developments in their ability to manage the disease and their attitudes towards the disease. The aim of the study is to compare the education given to individuals with Type 2 diabetes via mobile phone and the education given to individuals via brochures with conventional methods.

Read the detailed description

The use of telehealth technologies in the field of health is becoming more and more widespread. Telehealth has become one of the frequently used options in the follow-up process of chronic diseases such as diabetes, especially in recent years. Diabetes education is of great importance in the effective management of diabetes. Studies have shown that patients given diabetes education have positive developments in their ability to manage the disease and their attitudes towards the disease. The aim of the study is to compare the education given to individuals with Type 2 diabetes via mobile phone and the education given to individuals via brochures with conventional methods.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • Diabetes Mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 30 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Muğla Sıtkı Koçman University is the lead sponsor of 112 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Having a diagnosis of type 2 diabetes mellitus for at least 6 months,
  • Those between the ages of 18-65,
  • Receiving oral antidiabetic and/or insulin therapy,
  • Having a mobile phone capable of receiving and playing video messages,
  • Does not have hearing, speech and psychiatric problems that prevent communication,

Exclusion criteria

Exclusion Criteria:

  • Individuals who do not volunteered to participate in the study
  • Patients who have hearing, speech and psychiatric problems that prevent communication
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Telehealth Education (TE)

    After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.

    Other: TE

  • Active comparator
    Conventional Education (CE)

    Paper-based education forms will be given to the patients in the first group. Face-to-face conventional diabetes education will be carried out.

    Other: CE

Interventions

  • OtherTE

    After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.

  • OtherCE

    After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.

06

What researchers measure

Primary outcomes

  1. International Survey of Physical Activity (IPAQ)

    Physical activity assessment

    Time frame: 4 weeks

  2. Goal orientation in exercise measure (GOEM)

    Measurement of goal orientation in exercise

    Time frame: 4 weeks

  3. Mini Nutritional Assessment

    To evaluate the nutrition status of the patients

    Time frame: 4 weeks

  4. The Problem Areas in Diabetes Scale (PADS)

    PADS evaluates comprehensive diabetes evaluation. A total score is ranged between 0 - 100. Patients scoring 40 or higher may be at the level of "emotional burnout" and warrant special attention.

    Time frame: 4 weeks

07

Study locations

1 site
  • Muğla Training and Research Hospital
    Muğla, 48000, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05202470
Lead sponsor
Muğla Sıtkı Koçman University
Responsible party
Fatih Ozden (Principal Investigator, Muğla Sıtkı Koçman University) — Principal investigator
First posted
Jan 21, 2022
Start date
Jan 6, 2022
Primary completion
May 10, 2023
Completion
May 15, 2023
Last update
Jun 15, 2023

Study contacts

Serap Tuna, PhD
study chair · Muğla Sıtkı Koçman University
Emine Neşe Yeniçeri, MD
principal investigator · Muğla Sıtkı Koçman University
Cem Şahin, MD
principal investigator · Muğla Sıtkı Koçman University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion